Andrulis IL - Search Results

1

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium; McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Kuchenbaecker KB, et al. Among authors: andrulis il. JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112. JAMA. 2017. PMID: 28632866

2

Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.

Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. Phillips KA, et al. Among authors: andrulis il. J Natl Cancer Inst. 1999 Mar 3;91(5):469-73. doi: 10.1093/jnci/91.5.469. J Natl Cancer Inst. 1999. PMID: 10070948

3

Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.

Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, Andrulis IL, Lu J, Ho FC. Khoo US, et al. Among authors: andrulis il. Oncogene. 1999 Aug 12;18(32):4643-6. doi: 10.1038/sj.onc.1202847. Oncogene. 1999. PMID: 10467410

4

Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?

Phillips KA, Andrulis IL, Goodwin PJ. Phillips KA, et al. Among authors: andrulis il. J Clin Oncol. 1999 Nov;17(11):3653-63. doi: 10.1200/JCO.1999.17.11.3653. J Clin Oncol. 1999. PMID: 10550164 Review.

5

Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.

Phillips KA, Warner E, Meschino WS, Hunter J, Abdolell M, Glendon G, Andrulis IL, Goodwin PJ. Phillips KA, et al. Among authors: andrulis il. Clin Genet. 2000 May;57(5):376-83. doi: 10.1034/j.1399-0004.2000.570508.x. Clin Genet. 2000. PMID: 10852372

6

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. Yazici H, et al. Among authors: andrulis il. Br J Cancer. 2000 Sep;83(6):737-42. doi: 10.1054/bjoc.2000.1332. Br J Cancer. 2000. PMID: 10952777 Free PMC article.

7

BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.

Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. Yazici H, et al. Among authors: andrulis il. Hum Mutat. 2002 Jul;20(1):28-34. doi: 10.1002/humu.10090. Hum Mutat. 2002. PMID: 12112655

8

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.

Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS; Cooperative Family Registry for Breast Cancer studies. Andrulis IL, et al. Hum Mutat. 2002 Jul;20(1):65-73. doi: 10.1002/humu.10097. Hum Mutat. 2002. PMID: 12112659

9

HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.

Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. Quenneville LA, et al. Among authors: andrulis il. Cancer. 2002 Nov 15;95(10):2068-75. doi: 10.1002/cncr.10949. Cancer. 2002. PMID: 12412159 Free article.

10

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. Bull SB, et al. Among authors: andrulis il. J Clin Oncol. 2004 Jan 1;22(1):86-96. doi: 10.1200/JCO.2004.09.128. J Clin Oncol. 2004. PMID: 14701769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

469 results

Search Page